Nonsteroidal anti-inflammatory drugs: effects on kidney function

Nonsteroidal anti-inflammatory drugs (NSAIDs) are capable of inducing a variety of renal function abnormalities, particularly in high-risk patients with decreased renal blood perfusion who depend on prostaglandin synthesis to maintain normal renal function. Fluid retention is the most common NSAID-related renal complication, occurring to some degree in virtually all exposed individuals; however, clinically detectable edema occurs in less than 5% of patients and is readily reversible on discontinuation of the NSAID. Other electrolyte complications, notably hyperkalemia, are seen infrequently and occur in specific at-risk patients. The next most worrisome complication is acute deterioration of renal function, which occurs in high-risk patients and is also reversible. Nephrotic syndrome with interstitial nephritis is a rare problem of NSAID use and is reversible. Papillary necrosis is the only permanent complication of NSAIDs and is very rare. Altogether, these renal function abnormalities, with the exception of mild fluid retention, are clinically detectable in approximately 1% of exposed patients. Given the number of patients who take NSAIDs on a prescription or over-the-counter basis, the absolute number of at-risk patients is relatively large. Consequently, an appreciation for the risk factors and pathophysiology of NSAID-induced renal function abnormalities is required for optimal use of these drugs.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. D. ALTMAN, R.-L. DREISER, C. L. FISHER, W. F. CHASE, D. S. DREHER, and J. ZACHER Diclofenac Sodium Gel in Patients with Primary Hand Osteoarthritis: A Randomized, Double-blind, Placebo-controlled Trial J Rheumatol, September 1, 2009; 36(9): 1991 - 1999. [Abstract] [Full Text] [PDF]

				C. M. John, R. Shukla, and C. A Jones Using non-steroidal anti-inflammatory drugs (NSAIDs) in volume depleted children can precipitate acute renal failure BMJ Case Reports, May 11, 2009; 2009(may11_1): bcr1220081318 - bcr1220081318. [Abstract] [Full Text]

				P.-C. T. Pham, E. Toscano, P.-M. T. Pham, P.-A. T. Pham, S. V. Pham, and P.-T. T. Pham Pain management in patients with chronic kidney disease NDT Plus, April 1, 2009; 2(2): 111 - 118. [Abstract] [Full Text] [PDF]

				A. Aneja and M. E. Farkouh Review: Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 53 - 66. [Abstract] [PDF]

				D.-M. Kim, J. H. Chung, S. H. Yoon, and H. L. Kim Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3273 - 3276. [Abstract] [Full Text] [PDF]

				C. Mathews John, R. Shukla, and C. A Jones Using NSAID in volume depleted children can precipitate acute renal failure Arch. Dis. Child., June 1, 2007; 92(6): 524 - 526. [Abstract] [Full Text] [PDF]

				V. Schneider, L. E. Levesque, B. Zhang, T. Hutchinson, and J. M. Brophy Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis Am. J. Epidemiol., November 1, 2006; 164(9): 881 - 889. [Abstract] [Full Text] [PDF]

				W. Koppert, K. Frotsch, N. Huzurudin, W. Boswald, N. Griessinger, V. Weisbach, R. E. Schmieder, and J. Schuttler The Effects of Paracetamol and Parecoxib on Kidney Function in Elderly Patients Undergoing Orthopedic Surgery Anesth. Analg., November 1, 2006; 103(5): 1170 - 1176. [Abstract] [Full Text] [PDF]

				R. C. Harris and M. D. Breyer Update on Cyclooxygenase-2 Inhibitors Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 236 - 245. [Abstract] [Full Text] [PDF]

				R. A. Dionne, D. Haynes, J. S. Brahim, J. S. Rowan, and P.-H. Guivarc'h Analgesic Effect of Sustained-Release Flurbiprofen Administered at the Site of Tissue Injury in the Oral Surgery Model J. Clin. Pharmacol., December 1, 2004; 44(12): 1418 - 1424. [Abstract] [Full Text] [PDF]

				S. N Hartmann, C. M Rordorf, S. Milosavljev, J. M Branson, G. H Chales, R. R Juvin, P. Lafforgue, J. M. Le Parc, C. G Tavernier, and O. C Meyer Lumiracoxib Does Not Affect Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients Ann. Pharmacother., October 1, 2004; 38(10): 1582 - 1587. [Abstract] [Full Text] [PDF]

				G. C. Curhan, E. L. Knight, B. Rosner, S. E. Hankinson, and M. J. Stampfer Lifetime Nonnarcotic Analgesic Use and Decline in Renal Function in Women Arch Intern Med, July 26, 2004; 164(14): 1519 - 1524. [Abstract] [Full Text] [PDF]

				G. K Sandhu and C. A Heyneman Nephrotoxic Potential of Selective Cyclooxygenase-2 Inhibitors Ann. Pharmacother., April 1, 2004; 38(4): 700 - 704. [Abstract] [Full Text] [PDF]

				H.-F. Cheng and R. C. Harris Cyclooxygenases, the Kidney, and Hypertension Hypertension, March 1, 2004; 43(3): 525 - 530. [Abstract] [Full Text] [PDF]

				F. G. Silva Chemical-Induced Nephropathy: A Review of the Renal Tubulointerstitial Lesions in Humans Toxicol Pathol, February 1, 2004; 32(2_suppl): 71 - 84. [Abstract] [PDF]

				M. S. Joy The Renal Effects of Traditional Nonsteroidal Anti-Inflammatory Agents Versus Cyclooxygenase-2 Inhibitors Journal of Pharmacy Practice, October 1, 2002; 15(5): 383 - 391. [Abstract] [PDF]

				W. H. Beierwaltes Cyclooxygenase-2 products compensate for inhibition of nitric oxide regulation of renal perfusion Am J Physiol Renal Physiol, July 1, 2002; 283(1): F68 - F72. [Abstract] [Full Text] [PDF]

				P. A. MOORE and E. V. HERSH Celecoxib and rofecoxib: The role of COX-2 inhibitors in dental practice J Am Dent Assoc, April 1, 2001; 132(4): 451 - 456. [Abstract] [Full Text] [PDF]

				K. Saag, D. van der Heijde, C. Fisher, A. Samara, L. DeTora, J. Bolognese, R. Sperling, B. Daniels, and for the Osteoarthritis Studies Group Rofecoxib, a New Cyclooxygenase 2 Inhibitor, Shows Sustained Efficacy, Comparable With Other Nonsteroidal Anti-inflammatory Drugs: A 6-Week and a 1-Year Trial in Patients With Osteoarthritis Arch Fam Med, November 1, 2000; 9(10): 1124 - 1134. [Abstract] [Full Text] [PDF]

				H. Kim, M. Xu, Y. Lin, M. J. Cousins, R. P. Eckstein, V. Jordan, I. Power, and L. E. Mather Renal Dysfunction Associated with the Perioperative Use of Diclofenac Anesth. Analg., October 1, 1999; 89(4): 999 - 999. [Abstract] [Full Text] [PDF]

				P. Brooks, P. Emery, J. F. Evans, H. Fenner, C. J. Hawkey, C. Patrono, J. Smolen, F. Breedveld, R. Day, M. Dougados, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 Rheumatology, August 1, 1999; 38(8): 779 - 788. [Abstract] [Full Text] [PDF]

				M. Rahman and M. C. Smith Chronic Renal Insufficiency: A Diagnostic and Therapeutic Approach Arch Intern Med, September 14, 1998; 158(16): 1743 - 1752. [Abstract] [Full Text] [PDF]

				K. N. M. Khan, C. M. Venturini, R. T. Bunch, J. A. Brassard, A. T. Koki, D. L. Morris, B. E. Trump, T. J. Maziasz, and C. L. Alden Interspecies Differences in Renal Localization of Cyclooxygenase Isoforms: Implications in Nonsteroidal Antiinflammatory Drug-Related Nephrotoxicity Toxicol Pathol, September 1, 1998; 26(5): 612 - 620. [Abstract] [PDF]

				J. W. Verlander Normal Ultrastructure of the Kidney and Lower Urinary Tract Toxicol Pathol, January 1, 1998; 26(1): 1 - 17. [Abstract] [PDF]

				P. H. Bach and N. T. K. Thanh Renal Papillary Necrosis--40 Years On Toxicol Pathol, January 1, 1998; 26(1): 73 - 91. [Abstract] [PDF]

				B. Pal, A. Hutchinson, A. Bhattacharya, and A. Ralston Lesson of the Week: Cardiac arrest due to severe hyperkalaemia in patient taking nabumetone and low salt diet BMJ, December 2, 1995; 311(7018): 1486 - 1487. [Full Text]